FDA Could Face Lowest NME Count Post-PDUFA; Three Clear In November
This article was originally published in Pharmaceutical Approvals Monthly
FDA is entering the final month of the year with 15 new molecular entity approvals, following three clearances in November.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class